Lipella Pharmaceuticals Inc

NASDAQ:LIPOUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical deposition to the internal surface of the urinary bladder lumen using a proprietary drug delivery platform. LP-310 is the development name of its oral, liposomal formulation of tacrolimus specifically optimized for local delivery to oral mucosa. It is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). LP-410 is an oral rinse, like LP-310, but has a different containment system. LP-410 targets the underlying mechanisms of oral GVHD, potentially providing a safe and effective treatment option for affected individuals.

Contact Information

Headquarters

400 N Lexington St Ste Ll103PITTSBURGH, PA, United States 15208

Phone

412-901-0315

Fax

302-658-3694

Executives

Chairman of the Board, President, Chief Executive Officer, Treasurer, Company Secretary

Jonathan Kaufman

Chief Financial Officer

Douglas Johnston

Chief Medical Officer, Director

Micheal Chancellor

Independent Director

Lori Birder

Independent Director

Daniel Cohen